CHICAGO – Freeborn & Peters LLP is pleased to announce that the firm’s Intellectual Property Practice Group has been recognized within the annual Patexia Abbreviated New Drug Application (ANDA) Intelligence Report. Patexia, an IP analytics company and global IP community, is a trusted resource known in the intellectual property space for its transparency and extensive research. Inclusion in the report, according to Patexia, means that Freeborn & Peters LLP is in the top 10 percentile of this category of ANDA litigation.
“We are thrilled to hear that our talented Intellectual Property Group received recognition from Patexia for their expertise with ANDA/Hatch-Waxman Act litigation,” said William E. Russell, the Firm’s Co-Managing Partner. “The growing team’s experience in this category of IP law adds another dimension of capabilities for Freeborn’s overall legal services. It is gratifying to be included on a list that aims to help the IP community and both brand and generic pharmaceutical companies make decisions about their legal partners.”
Patexia evaluated more than 250 local counsel, 140 law firms, and 1,105 attorneys based on ANDA activity and performance, which was measured and verified by an independent third-party. The research team analyzed the outcome of 976 ANDA cases filed between June 1, 2017 and June 1, 2020, which involved 319 brand and generic pharmaceutical companies, 182 of which were named as plaintiffs and 180 were named as defendants.
Freeborn’s Intellectual Property Practice Group provides counsel for copyright protection and enforcement, IP licensing and transaction counseling, trademark protection, enforcement and counseling, and more. The Intellectual Property teams help clients grow their IP portfolio efficiently by focusing attention and resources on the most valuable IP assets. They advocate by negotiating a client’s purchase, sale, or license of IP rights.
To learn more about Patexia, visit https://patexia.com.